Biogen news today. APLS shares are up during Tuesday’s premarket session following news that Biogen Inc. , March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. Mar 24, 2025 · Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint New building will be designed to foster collaboration and spark innovation; Biogen plans to relocate Cambridge-based employees to the new site in 2028 CAMBRIDGE, Mass. (Nasdaq: APLS) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41. manufacturing footprint Biogen's largest manufacturing footprint is located in North Carolina’s Research Triangle Park (RTP). 6B Deal With Biogen Apellis Pharmaceuticals stock more than doubled after Biogen said it will acquire the biopharmaceutical firm. Jan 15, 2026 · Our medicines aim to improve the well-being of people around the world. 2 days ago · Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. and WALTHAM, Mass. BIIB has agreed to acquire Apellis for $41 per share in cash or approximately 2 days ago · What's going on at Biogen (NASDAQ:BIIB)? Read today's BIIB news from trusted media outlets at MarketBeat. 00 per share in cash at closing, or 1 day ago · Home News Markets Equity APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5. Sep 18, 2025 · Biogen will drive end-to-end development, manufacturing and commercialization of ThecaFlex DRx™. 1 day ago · Biogen struck a deal Tuesday to buy Apellis Pharmaceuticals for $5. The buyout adds two approved drugs to Biogen's pipeline. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. 1 day ago · CAMBRIDGE, Mass. To deliver on this, we seek talent with unique skill sets to fuel our innovation. 6 billion, building on its aspirations in nephrology. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and Mar 3, 2026 · Biogen is dedicated to addressing challenging diseases by leveraging cutting-edge science and driving an innovative pipeline of potential breakthrough therapies in neurology, immunology, and rare diseases. Jan 22, 2026 · Our U. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. 6 billion. We focus on areas where our expertise can deliver the greatest value to patients and make a meaningful impact on health outcomes. Browse available job openings at Biogen locations worldwide. As the state's largest biotech employer and one of the top five biopharmaceutical employers, Biogen employs over 1,500 people and more than 400 skilled contractors across its Wake County and Durham County We drive innovation to defeat some of the most complex and devastating diseases. Our approach is to take bold risks, balanced Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. . , March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc Jul 21, 2025 · Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen’s late-stage clinical pipeline. In return, we offer employees the opportunity to grow, contribute to a niche field, and belong to an exceptional culture that fosters well-being. Upon closing, Alcyone employees who will join Biogen will be integrated into the company’s product delivery solutions team, building upon the existing portfolio and expertise in drug-device combination products. 1 day ago · In today's second sizeable M&A deal, Biogen has agreed to buy Apellis for around $5. Apellis Pharmaceuticals Inc. S. bjjhxh wiloken bmm ybfv ssev